It will be an absolute disaster if a large number of people only take one dose of the vaccine. It is very likely that protective immunity will wane rapidly in individuals who only take the first shot and efficacy will be nowhere near the 95% reported after the two-dose regimen.
-
-
Replying to @CarlosdelRio7 @michaelmina_lab
I agree. Too much uncertainty in short- and long-term efficacy. And the optics of changing the plan now, for a regimen that hasn’t been tested directly, are not great. Follow on studies can assess non-inferiority of a one dose regimen, but for now the data support two doses.
8 replies 3 retweets 99 likes -
Replying to @nataliexdean @CarlosdelRio7
Yes, the data support two doses. I agree. The data that we have also may support one dose. I'm the first to say that we don't have good data - even w two doses - that go out past a few months. I'm terrified that efficacy will fall fast once plasmablasts die off. 1/
3 replies 1 retweet 37 likes -
If we think about this globally - just how difficult its going to be to get the vaccine to most of the world - I do think it is very much worth taking a couple more months and trying the same study in people who otherwise wouldn't be first in line. We can only gain from it. 2/2
4 replies 1 retweet 28 likes -
What about an immediate call for volunteers for a randomized group among the many millions who'll get the first shot? Data-wise, some of the initial groups aren't that high risk at the moment (<65 HCWs). The vaccine shortage is going to have huge implications on overall deaths.
2 replies 6 retweets 27 likes -
Replying to @zeynep @michaelmina_lab and
I hear all the hesitations, but the other side of the equation—potentially doubling the number vaccinated in the short term—is not a minor number.
3 replies 0 retweets 12 likes -
Or we simply set up a single dose trial in people unlikely to receive a vaccine until May or June. It will help inform the approach for the world and will give terrific medium term information.
1 reply 3 retweets 25 likes -
Replying to @michaelmina_lab @zeynep and
Easier said than done when "we" is Pfizer. If data is similar for Moderna that's another matter. I think 100% should be explored and def encouraging that lower titer Ab could be protective but would not give to high-risk folks since unknown impact on B cell memory, Ab kinetics
2 replies 0 retweets 0 likes -
Replying to @k_stephensonMD @michaelmina_lab and
Moderna medical people have pretty much said so on their investor calls but waiting for the proper medical readout (soon!). Guess we'll see. On Pfizer, agree on no such trials on higher-risk folks. There's already data from phase I/II that suggest no to this for >65.
2 replies 0 retweets 1 like -
Replying to @zeynep @michaelmina_lab and
A signal for lower Ab threshold for is very encouraging for dose-sparing regimens which need testing ASAP. I think half-dose x 2 doses might be the sweet spot.
1 reply 0 retweets 0 likes
Why aren't we launching all these trials among the millions who are about to get vaccinated? *sigh* Look at RECOVERY. When everyone was at the kitchen sink stage, they randomized and followed-up and gave us 1/3 reduction in mortality in severe disease with dexa.
-
-
Replying to @zeynep @michaelmina_lab and
Good news is Johnson&Johnson vaccine is testing both 1 and 2 dose regimens. Read out expected for Jan so hopefully fast roll out by Feb.
0 replies 0 retweets 1 likeThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.